A5006057019- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Renal Transplantation Outcomes and Treatments
- Acute Myeloid Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- Immune Cell Function and Interaction
- Polyomavirus and related diseases
- Frailty in Older Adults
- Diabetes and associated disorders
- Cancer survivorship and care
- CAR-T cell therapy research
- Nutrition and Health in Aging
- Chronic Myeloid Leukemia Treatments
- Oral health in cancer treatment
- Chronic Lymphocytic Leukemia Research
- T-cell and B-cell Immunology
- Mesenchymal stem cell research
- Neutropenia and Cancer Infections
- Multiple Myeloma Research and Treatments
- Platelet Disorders and Treatments
- Atherosclerosis and Cardiovascular Diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cytomegalovirus and herpesvirus research
- Gut microbiota and health
University of Minnesota
2019-2025
National Institutes of Health
2024-2025
Center for Cancer Research
2024-2025
National Cancer Institute
2024-2025
University of Minnesota System
2024
University of Minnesota Medical Center
2021-2023
National Marrow Donor Program
2023
Twin Cities Orthopedics
2022
University Hospitals Seidman Cancer Center
2017-2021
NHS Blood and Transplant
2020-2021
In patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT), a calcineurin inhibitor plus methotrexate has been standard prophylaxis against graft-versus-host disease (GVHD). A phase 2 study indicated the potential superiority of post-transplantation regimen cyclophosphamide, tacrolimus, and mycophenolate mofetil.
The population of cancer survivors has markedly increased due to the rapid improvements in treatment. However, experience accelerated aging, which leads chronic diseases and other age-related conditions, such as frailty. Those conditions may persist years after diagnosis Cellular senescence, a hallmark is one mechanisms that contribute aging survivors. Several measures, including measures based on clinical markers biomarkers, have been proposed estimate process, some them shown associations...
The BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) results in superior GVHD-free, relapse-free survival (GRFS) compared Tac/methotrexate (MTX) prophylaxis. This companion study assesses the effect of these regimens on patient-reported outcomes (PROs). Using Lee Chronic GVHD Symptom Score PROMIS subscales (physical function, GI symptoms, social role...
Chronic graft-versus-host disease (cGVHD) is an immune-mediated, heterogeneous, multiorgan complication affecting allogeneic hematopoietic cell transplantation recipients, leading to increased morbidity, mortality, and decline in health-related quality-of-life. Advances understanding the complex pathophysiology, collaborative efforts lead by National Institutes of Health standardize criteria for clinical trials, led bench-to-bedside resulting development 4 US Food Drug...
Successful hematopoietic cell transplant requires immunosuppression to prevent graft-versus-host disease (GVHD), a lethal, T-cell-mediated post-transplant complication. The phase 3 BMT CTN 1703 trial demonstrated superior GVHD-free/relapse-free survival for cyclophosphamide (PT-Cy)-based GVHD prophylaxis versus tacrolimus/methotrexate (Tac/MTX), but did not improve overall survival. To compare T-cell biology between regimens, 324 patients were co-enrolled onto 1801 ( NCT03959241 ). We...
Microbiome dysbiosis has been associated with adverse outcomes of hematopoietic cell transplantation (HCT). We hypothesized that exposure to high-dose melphalan and antimicrobials in patients undergoing autologous HCT for plasma disorders results oral gastrointestinal microbial dysbiosis, which turn is regimen-related toxicities. conducted a prospective study describing the longitudinal changes bacteriome mycobiome this patient population. Our findings show microbiome composition present at...
Socioeconomic status (SES) and race/ethnicity have been associated with the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HCT). Certain aspects graft-versus-host disease (GVHD) management, such as need for long-term care, prolonged immunosuppressive treatment, close follow-up complications, may exacerbate disparities. Adults (≥18 years) reported to Center International Blood Marrow Transplant Research who underwent a first allo-HCT acute leukemia, myelodysplastic...
Abstract Acute graft-versus-host disease (aGVHD) is a potentially fatal complication of allogeneic hematopoietic cell transplantation that fails to improve with intense immunosuppression in some patients. We hypothesized urinary-derived human chorionic gonadotropin (uhCG) could help facilitate resolution life-threatening aGVHD when added as supportive care via 2 potential mechanisms: immunomodulation (akin its role pregnancy) and supplementation epidermal growth factor (EGF; aid epithelial...
Mycophenolate mofetil (MMF) is an important immunosuppressant used after allogeneic hematopoietic cell transplantation (HCT). MMF has a narrow therapeutic index, and blood concentrations of mycophenolic acid (MPA), the active component MMF, are highly variable. Low MPA associated with risk graft-versus-host disease (GVHD), whereas high toxicity. Reasons for variability not well known may include presence β-glucuronidase-producing bacteria in gastrointestinal tract, which enhance...
Autologous hematopoietic stem cell transplantation (ASCT) improves survival for patients with chemotherapy-sensitive lymphoma. Validated scoring systems are used in the clinical setting to predict treatment toxicity and survival; however, complications related disease still occur, highlighting challenges optimal patient selection need novel predictors. Analysis of body composition muscle mass can provide an objective assessment identify vulnerable populations, as sarcopenia frailty have been...
Prior studies have demonstrated an association between cutaneous chronic graft-vs-host disease (cGVHD) and mortality. Assessment of the prognostic value different measures severity would assist in risk stratification.
Chronic graft vs. host disease (GVHD) treatment response is assessed using NIH Consensus criteria in clinical trials, and by clinician assessment routine practice. Patient-reported central to the experience of chronic GVHD manifestations as well benefit toxicity, but how they correlate with clinician- or NIH-responses has not been studied. We aimed characterize 6-month patient-reported response, determine associated baseline organ features changes, evaluate which patientreported quality life...